OpGen, Inc. (OPGN)
USD 1.07
(-3.6%)
USD 1.07
(-3.6%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 13.04 Million USD | -12.1% |
| 2022 | 14.83 Million USD | -41.07% |
| 2021 | 25.17 Million USD | 10.2% |
| 2020 | 22.84 Million USD | 623.05% |
| 2019 | 3.15 Million USD | 66.71% |
| 2018 | 1.89 Million USD | 46.26% |
| 2017 | 1.29 Million USD | -4.34% |
| 2016 | 1.35 Million USD | -16.87% |
| 2015 | 1.62 Million USD | -49.69% |
| 2014 | 3.23 Million USD | 824.22% |
| 2013 | 350.52 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 13.46 Million USD | 3.16% |
| 2024 Q1 | 13.05 Million USD | 0.09% |
| 2023 Q1 | 13.94 Million USD | -6.04% |
| 2023 Q3 | 12.55 Million USD | -1.14% |
| 2023 Q4 | 13.04 Million USD | 3.91% |
| 2023 Q2 | 12.69 Million USD | -8.93% |
| 2023 FY | 13.04 Million USD | -12.1% |
| 2022 Q3 | 15.43 Million USD | -14.45% |
| 2022 Q1 | 25.68 Million USD | 2.02% |
| 2022 FY | 14.83 Million USD | -41.07% |
| 2022 Q4 | 14.83 Million USD | -3.88% |
| 2022 Q2 | 18.04 Million USD | -29.75% |
| 2021 Q1 | 23.51 Million USD | 2.91% |
| 2021 Q2 | 24.57 Million USD | 4.5% |
| 2021 FY | 25.17 Million USD | 10.2% |
| 2021 Q3 | 24.79 Million USD | 0.9% |
| 2021 Q4 | 25.17 Million USD | 1.56% |
| 2020 FY | 22.84 Million USD | 623.05% |
| 2020 Q3 | 21.43 Million USD | 3.09% |
| 2020 Q2 | 20.79 Million USD | 705.56% |
| 2020 Q1 | 2.58 Million USD | -18.31% |
| 2020 Q4 | 22.84 Million USD | 6.58% |
| 2019 Q3 | 3.67 Million USD | -3.88% |
| 2019 FY | 3.15 Million USD | 66.71% |
| 2019 Q4 | 3.15 Million USD | -14.05% |
| 2019 Q2 | 3.82 Million USD | -5.32% |
| 2019 Q1 | 4.04 Million USD | 113.14% |
| 2018 Q3 | 1.96 Million USD | 0.37% |
| 2018 Q4 | 1.89 Million USD | -3.36% |
| 2018 FY | 1.89 Million USD | 46.26% |
| 2018 Q1 | 1.48 Million USD | 14.21% |
| 2018 Q2 | 1.95 Million USD | 32.03% |
| 2017 FY | 1.29 Million USD | -4.34% |
| 2017 Q3 | 1.38 Million USD | -30.16% |
| 2017 Q2 | 1.97 Million USD | 54.73% |
| 2017 Q4 | 1.29 Million USD | -6.11% |
| 2017 Q1 | 1.27 Million USD | -5.73% |
| 2016 Q1 | 1.51 Million USD | -7.07% |
| 2016 Q3 | 1.49 Million USD | -8.6% |
| 2016 Q2 | 1.63 Million USD | 7.8% |
| 2016 FY | 1.35 Million USD | -16.87% |
| 2016 Q4 | 1.35 Million USD | -9.21% |
| 2015 FY | 1.62 Million USD | -49.69% |
| 2015 Q4 | 1.62 Million USD | 5.4% |
| 2015 Q2 | 331.83 Thousand USD | -91.24% |
| 2015 Q3 | 1.54 Million USD | 365.94% |
| 2015 Q1 | 3.78 Million USD | 16.97% |
| 2014 FY | 3.23 Million USD | 824.22% |
| 2014 Q4 | 3.23 Million USD | 83.42% |
| 2014 Q1 | - USD | -100.0% |
| 2014 Q3 | 1.76 Million USD | 0.0% |
| 2013 Q4 | 244.56 Thousand USD | 0.0% |
| 2013 FY | 350.52 Thousand USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bionano Genomics, Inc. | 87.94 Million USD | 85.169% |
| Prenetics Global Limited | 2.36 Million USD | -450.509% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -261.422% |
| CareDx, Inc | 34.22 Million USD | 61.884% |
| Exact Sciences Corporation | 2.55 Billion USD | 99.489% |
| Exagen Inc. | 23.72 Million USD | 45.012% |
| Inotiv, Inc. | 417.64 Million USD | 96.877% |
| Guardant Health, Inc. | 1.35 Billion USD | 99.036% |
| Biodesix, Inc. | 60.69 Million USD | 78.508% |
| BioNexus Gene Lab Corp. | 133.39 Thousand USD | -9678.257% |
| Precipio, Inc. | 1.11 Million USD | -1068.791% |
| iSpecimen Inc. | 196.24 Thousand USD | -6546.678% |
| Natera, Inc. | 441.99 Million USD | 97.049% |
| Aspira Women's Health Inc. | 2.26 Million USD | -475.627% |
| Standard BioTools Inc. | 98.21 Million USD | 86.719% |
| 23andMe Holding Co. | 76.51 Million USD | 82.953% |
| Castle Biosciences, Inc. | 15.31 Million USD | 14.803% |
| Personalis, Inc. | 48.96 Million USD | 73.36% |
| Aclaris Therapeutics, Inc. | 426 Thousand USD | -2961.903% |
| Applied DNA Sciences, Inc. | 1.23 Million USD | -953.815% |
| T2 Biosystems, Inc. | 49.49 Million USD | 73.648% |
| Myriad Genetics, Inc. | 145 Million USD | 91.004% |
| ICON Public Limited Company | 3.93 Billion USD | 99.669% |
| NeoGenomics, Inc. | 611.67 Million USD | 97.868% |
| Star Equity Holdings, Inc. | 3.6 Million USD | -261.422% |
| IDEXX Laboratories, Inc. | 947.88 Million USD | 98.624% |
| RadNet, Inc. | 1.49 Billion USD | 99.125% |
| MDxHealth SA | 41.26 Million USD | 68.39% |
| Psychemedics Corporation | 2.29 Million USD | -467.611% |
| Illumina, Inc. | 2.26 Billion USD | 99.423% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 94.06 Million USD | 86.134% |
| DarioHealth Corp. | 29.54 Million USD | 55.845% |
| Fulgent Genetics, Inc. | 14.9 Million USD | 12.499% |
| Sera Prognostics, Inc. | 1.85 Million USD | -602.029% |
| ENDRA Life Sciences Inc. | 394.4 Thousand USD | -3207.203% |
| OPKO Health, Inc. | 326.56 Million USD | 96.006% |
| Medpace Holdings, Inc. | 142.12 Million USD | 90.822% |
| Neogen Corporation | 906.23 Million USD | 98.561% |
| Intelligent Bio Solutions Inc. | 871.44 Thousand USD | -1396.799% |
| Prenetics Global Limited | 2.36 Million USD | -450.509% |
| Mainz Biomed B.V. | 7.42 Million USD | -75.773% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -726.263% |
| Trinity Biotech plc | 67.42 Million USD | 80.655% |
| Neuronetics, Inc. | 62.47 Million USD | 79.121% |
| Sotera Health Company | 2.32 Billion USD | 99.439% |
| bioAffinity Technologies, Inc. | 1.57 Million USD | -726.263% |